What happened
After management decided to dial back revenue expectations for 2017, shares of Glaukos (GKOS 1.05%), a medical device maker focused on diseases of the eye, tumbled 13% in September, according to data from S&P Global Market Intelligence.
So what
Glaukos' management team held an investor day in mid-September. Here's a review of the key takeaways from the presentation:
- The company's iDose Travoprost product candidate -- which is an implantable device that delivers medication from within the eye for an extended period of time -- performed very well in phase 2 trials. Intraocular pressure declined by 8 mm Hg during a nine-month period with no incidents of hyperemia reported. The company said that it plans to move forward with a phase 3 trial in early 2018.
- Glaukos plans to submit an Investigational Device Evaluation (IDE) filing with the FDA in the fourth quarter for its iStent infinite product candidate. The iStent infinite is a three-stent trabecular bypass solution for treating glaucoma. Management expects this device to be a hit with patients who do not want to undergo invasive glaucoma surgery.
- Management revised its sales expectations for the third quarter and full year. Sales in the third quarter are expected to land between $38 million and $40 million (down from $41 million to $43 million). For the full year, sales guidance was revised downward to a range of $155 million to $160 million (compared to $162 million to $167 million previously). Management largely blamed the soft guidance on commercial carrier reimbursement, recent hurricanes, reimbursement changes in Australia, and new competition.
Wall Street responded to the downward guidance by deflating the company's share price.
Image source: Getty Images.
Now what
Glaukos' iStent has been a smash hit since launch. In fact, the company's top-line growth has exceeded 40% for 16 quarters in a row. Predictably, that kind of success hasn't gone unnoticed by the big players in eye care. Last year, healthcare giant Novartis acquired Transcend Medical to get its hands on the company's CyPass Micro-Stent. Since the CyPass was approved last year and competes directly with Glaukos' iStent for certain types of glaucoma patients, it is understandable that Wall Street got spooked by the downward revision to guidance.
With the iStent infinite and iDose Travoprost performing so well in clinical trials, Glaukos' days of hyper-growth are probably not over. What's more, the world's population is aging, so the demand for glaucoma treatments looks poised to rise substantially. While Glaukos' stock remains very expensive -- shares are still valued at north of eight times sales after including September's drop -- I think that right now is a fine time for growth-focused investors to give this stock a hard look.
